RYTM Quote, Financials, Valuation and Earnings

Cytokinetics has a net margin of -103.5% compared to Rhythm Pharmaceuticals's net margin of -886.28%. Rhythm Pharmaceuticals's return on equity of -178.94% beat Cytokinetics's return on equity of --.

Rhythm Pharmaceuticals has a consensus price target of $75.25, signalling upside risk potential of 44.82%. On the other hand Cytokinetics has an analysts' consensus of $78.60 which suggests that it could grow by 95.28%. Given that Cytokinetics has higher upside potential than Rhythm Pharmaceuticals, analysts believe Cytokinetics is more attractive than Rhythm Pharmaceuticals.

Rhythm Pharmaceuticals has a beta of 2.321, which suggesting that the stock is 132.096% more volatile than S&P 500. In comparison Cytokinetics has a beta of 0.938, suggesting its less volatile than the S&P 500 by 6.231%.

Rhythm Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cytokinetics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rhythm Pharmaceuticals pays -- of its earnings as a dividend. Cytokinetics pays out -- of its earnings as a dividend.

Rhythm Pharmaceuticals quarterly revenues are $41.8M, which are larger than Cytokinetics quarterly revenues of $16.9M. Rhythm Pharmaceuticals's net income of -$43.3M is higher than Cytokinetics's net income of -$150M. Notably, Rhythm Pharmaceuticals's price-to-earnings ratio is -- while Cytokinetics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rhythm Pharmaceuticals is 24.36x versus 243.46x for Cytokinetics. Usually stocks with elevated PS ratios are considered overvalued.

Geron has a net margin of -103.5% compared to Rhythm Pharmaceuticals's net margin of -53.33%. Rhythm Pharmaceuticals's return on equity of -178.94% beat Geron's return on equity of -59.29%.

Rhythm Pharmaceuticals has a consensus price target of $75.25, signalling upside risk potential of 44.82%. On the other hand Geron has an analysts' consensus of $4.50 which suggests that it could grow by 183.02%. Given that Geron has higher upside potential than Rhythm Pharmaceuticals, analysts believe Geron is more attractive than Rhythm Pharmaceuticals.

Rhythm Pharmaceuticals has a beta of 2.321, which suggesting that the stock is 132.096% more volatile than S&P 500. In comparison Geron has a beta of 0.661, suggesting its less volatile than the S&P 500 by 33.916%.

Rhythm Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Geron offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rhythm Pharmaceuticals pays -- of its earnings as a dividend. Geron pays out -- of its earnings as a dividend.

Rhythm Pharmaceuticals quarterly revenues are $41.8M, which are smaller than Geron quarterly revenues of $47.5M. Rhythm Pharmaceuticals's net income of -$43.3M is lower than Geron's net income of -$25.4M. Notably, Rhythm Pharmaceuticals's price-to-earnings ratio is -- while Geron's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rhythm Pharmaceuticals is 24.36x versus 13.34x for Geron. Usually stocks with elevated PS ratios are considered overvalued.

Madrigal Pharmaceuticals has a net margin of -103.5% compared to Rhythm Pharmaceuticals's net margin of -57.51%. Rhythm Pharmaceuticals's return on equity of -178.94% beat Madrigal Pharmaceuticals's return on equity of -63.91%.

Rhythm Pharmaceuticals has a consensus price target of $75.25, signalling upside risk potential of 44.82%. On the other hand Madrigal Pharmaceuticals has an analysts' consensus of $414.07 which suggests that it could grow by 23.75%. Given that Rhythm Pharmaceuticals has higher upside potential than Madrigal Pharmaceuticals, analysts believe Rhythm Pharmaceuticals is more attractive than Madrigal Pharmaceuticals.

Rhythm Pharmaceuticals has a beta of 2.321, which suggesting that the stock is 132.096% more volatile than S&P 500. In comparison Madrigal Pharmaceuticals has a beta of -0.683, suggesting its less volatile than the S&P 500 by 168.299%.

Rhythm Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Madrigal Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rhythm Pharmaceuticals pays -- of its earnings as a dividend. Madrigal Pharmaceuticals pays out -- of its earnings as a dividend.

Rhythm Pharmaceuticals quarterly revenues are $41.8M, which are smaller than Madrigal Pharmaceuticals quarterly revenues of $103.3M. Rhythm Pharmaceuticals's net income of -$43.3M is higher than Madrigal Pharmaceuticals's net income of -$59.4M. Notably, Rhythm Pharmaceuticals's price-to-earnings ratio is -- while Madrigal Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rhythm Pharmaceuticals is 24.36x versus -- for Madrigal Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals has a net margin of -103.5% compared to Rhythm Pharmaceuticals's net margin of 24.22%. Rhythm Pharmaceuticals's return on equity of -178.94% beat Regeneron Pharmaceuticals's return on equity of 15.78%.

Rhythm Pharmaceuticals has a consensus price target of $75.25, signalling upside risk potential of 44.82%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $915.34 which suggests that it could grow by 46.52%. Given that Regeneron Pharmaceuticals has higher upside potential than Rhythm Pharmaceuticals, analysts believe Regeneron Pharmaceuticals is more attractive than Rhythm Pharmaceuticals.

Rhythm Pharmaceuticals has a beta of 2.321, which suggesting that the stock is 132.096% more volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.437, suggesting its less volatile than the S&P 500 by 56.337%.

Rhythm Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals offers a yield of 0.14% to investors and pays a quarterly dividend of $0.88 per share. Rhythm Pharmaceuticals pays -- of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend.

Rhythm Pharmaceuticals quarterly revenues are $41.8M, which are smaller than Regeneron Pharmaceuticals quarterly revenues of $3.8B. Rhythm Pharmaceuticals's net income of -$43.3M is lower than Regeneron Pharmaceuticals's net income of $917.7M. Notably, Rhythm Pharmaceuticals's price-to-earnings ratio is -- while Regeneron Pharmaceuticals's PE ratio is 16.34x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rhythm Pharmaceuticals is 24.36x versus 5.07x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.